Alle Studien
Aktiv, aber nicht rekrutierendPHASE2INTERVENTIONELL

Test der Zugabe des Medikaments Relugolix zur üblichen Strahlentherapie bei fortgeschrittenem Prostatakrebs, Die NRG Promethean-Studie

This study, called NRG Promethean, is for men with a type of prostate cancer that has spread to a few other places in the body, but is still responding to hormone treatments. It compares two approaches: receiving standard radiation therapy by itself, or having radiation therapy along with a new study drug called relugolix. Relugolix works by lowering the amount of testosterone in the body, which can help slow down the growth of prostate cancer. Researchers want to find out if adding relugolix to radiation therapy is better at stopping the cancer from spreading further. The study will also look at side effects and how treatments affect men's quality of life.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE2
Sponsor
NRG Oncology
Einschreibeziel
194
Starten
20. Apr 2022
Geschätzte Fertigstellung
01 Feb 2029

Worum geht es in dieser Studie?

This study is called the NRG Promethean study and it focuses on men who have prostate cancer that has spread to a limited number of other parts of their body, known as 'oligometastatic' prostate cancer. This type of cancer is still sensitive to treatments that reduce male hormones. Currently, the usual treatment for this is radiation therapy, which uses strong energy beams to kill cancer cells.

The study wants to see if adding an oral drug called relugolix to this standard radiation therapy makes the treatment more effective. Relugolix works by lowering the level of testosterone in the body. Since prostate cancer often relies on testosterone to grow, reducing this hormone can help slow or stop the cancer's growth. The main goal is to find out if combining relugolix with radiation therapy can better prevent new cancer spots from appearing or stop the existing ones from growing.

Researchers will compare men who receive just the radiation therapy with those who receive radiation therapy plus relugolix. They will track key things like how long patients go without their cancer noticeably spreading, their quality of life, and any side effects. This will help doctors understand if this new combination treatment could be a better option for men with this specific type of prostate cancer.

Wichtige Erkenntnisse

  • This study investigates adding relugolix to standard radiation for specific prostate cancer.
  • Relugolix aims to lower testosterone, which can impact prostate cancer growth.
  • You might receive the active drug or a placebo, alongside radiation.
  • The main goal is to see if the combination better prevents cancer spread.
  • Your quality of life and side effects will be carefully monitored.
  • Participation involves daily medication for six months and regular check-ups.

Wer könnte berechtigt sein?

This study is looking for men aged 18 or older who have been diagnosed with prostate cancer. This cancer must have spread to a few, limited areas in their bones or other soft tissues of the body, but it's still manageable with hormone treatments. You would have had a specific scan (like a PSMA PET scan) recently to show these areas.

To join, you must have already had previous treatments for your prostate cancer that aimed to cure it, such as surgery (prostatectomy) or radiation therapy to the prostate area. You also need to be generally well enough to take part in the study, as assessed by a quick health check.

However, if your cancer has spread very widely, or if you haven't received prior curative-intent treatment for your prostate, this study might not be suitable for you.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you a man aged 18 or older?
  2. Do you have prostate cancer that has spread to 1 to 5 spots in your bones or soft tissues?
  3. Is your prostate cancer still responding to hormone treatments?
  4. Have you previously had surgery or radiation treatment for your prostate cancer?
  5. Are you generally well enough to take part in a study?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to join this study, your involvement would last for about six months of active treatment, with follow-up appointments afterwards. You would be randomly assigned to one of two groups. One group will take a placebo (a dummy pill that looks like the real drug but contains no active medicine) every day for about six months. The other group will take relugolix every day for the same period. Both groups will also receive their usual radiation therapy, which typically lasts for 1 to 3 weeks.

Throughout the study, you'll have various tests and scans, such as bone scans, CT scans, and special PET scans, to monitor your cancer and check how you're responding to treatment. You'll also answer questionnaires about your health and how you're feeling, including questions about your sexual health and general well-being. These assessments will help the study team understand the effects of the treatment and manage any side effects. You'll have regular clinic visits, and the study will oversee your progress and health for an extended period.

Potenzielle Risiken und Vorteile

Participating in this study might offer potential benefits, such as receiving a new treatment (relugolix) that could potentially improve the effectiveness of radiation therapy in preventing your prostate cancer from spreading further. However, it's also possible that you could receive the placebo. There are potential risks, including side effects from relugolix, which works by reducing testosterone, or from the radiation therapy. The study team will closely monitor you for any side effects. You have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Locations (245)

  • Cancer Center at Saint Joseph's
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten
  • Alta Bates Summit Medical Center-Herrick Campus
    Verifizierte Postleitzahl
    Berkeley, Vereinigte Staaten
  • Tower Cancer Research Foundation
    Verifizierte Postleitzahl
    Beverly Hills, Vereinigte Staaten
  • Marin General Hospital
    Verifizierte Postleitzahl
    Greenbrae, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
    Verifizierte Postleitzahl
    Irvine, Vereinigte Staaten
  • Los Angeles General Medical Center
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • USC / Norris Comprehensive Cancer Center
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • Cedars Sinai Medical Center
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • Memorial Medical Center
    Verifizierte Postleitzahl
    Modesto, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten
  • Sutter Medical Center Sacramento
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten
  • Sutter Pacific Medical Foundation
    Verifizierte Postleitzahl
    Santa Rosa, Vereinigte Staaten

Häufige Fragen

What is 'oligometastatic' prostate cancer?

This means your prostate cancer has spread to a small, limited number of other spots in your body, rather than very widely.

What is relugolix?

Relugolix is a drug that lowers testosterone levels in the body, which can help slow down the growth of prostate cancer cells.

Was ist ein 'Placebo'?

A placebo is a dummy pill with no active medicine, used in studies to compare against the active drug and see what real effects the drug has.

How long will I take the study drug?

You would take the study drug (relugolix or placebo) every day for about six months.

Will this study affect my usual doctor’s care?

No, joining a study like this should not affect your regular medical care. Your doctors will work together.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.